Charles Zhou
Stock Analyst at Guggenheim
(2.80)
# 1,968
Out of 5,090 analysts
11
Total ratings
62.5%
Success rate
24.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhou
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COGT Cogent Biosciences | Maintains: Buy | $17 → $20 | $38.77 | -48.41% | 2 | Aug 25, 2025 | |
| FUTU Futu Holdings | Maintains: Buy | $130 → $136 | $171.30 | -20.61% | 3 | Mar 17, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $16 | $26.69 | -40.05% | 1 | Mar 8, 2023 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.37 | - | 1 | May 5, 2022 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $56 | $1.19 | +4,605.88% | 1 | Aug 2, 2021 | |
| RPTX Repare Therapeutics | Initiates: Buy | $46 | $2.22 | +1,976.75% | 1 | Jun 28, 2021 | |
| QD Qudian | Downgrades: Neutral | n/a | $4.89 | - | 2 | Jan 22, 2020 |
Cogent Biosciences
Aug 25, 2025
Maintains: Buy
Price Target: $17 → $20
Current: $38.77
Upside: -48.41%
Futu Holdings
Mar 17, 2025
Maintains: Buy
Price Target: $130 → $136
Current: $171.30
Upside: -20.61%
Zymeworks
Mar 8, 2023
Reiterates: Buy
Price Target: $16
Current: $26.69
Upside: -40.05%
MacroGenics
May 5, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.37
Upside: -
PMV Pharmaceuticals
Aug 2, 2021
Initiates: Buy
Price Target: $56
Current: $1.19
Upside: +4,605.88%
Repare Therapeutics
Jun 28, 2021
Initiates: Buy
Price Target: $46
Current: $2.22
Upside: +1,976.75%
Qudian
Jan 22, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.89
Upside: -